Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Medtronic: Receives FDA go-ahead to market its Jewel Plus Active Can (Model 7220C) implantable-cardioverter-defibrillator, the company announces May 10. The 34-joule device incorporates Medtronic's Flashback memory feature, which Medtronic says "provides key information about the history and onset of tachyarrhythmia episodes," and the firm's Marker Channel technology, which "aids precise diagnosis by indicating device response." In addition, the device features a "new interval plotting capability (graphic display of episode characteristics) for stored tachyarrhythmia episodes," the firm says. Medtronic also releases commercially its Transvene tined silicone lead (Model 6934S), which it says is the "world's first tachyarrhythmia lead employing a steroid-eluting electrode to minimize scar-tissue formation at the endocardial wall and thus enhance sensing performance"...

You may also be interested in...

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Scrip’s Rough Guide On The State Of RNAi

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts